Researchers identify a new way to target treatment-resistant cancers
An international team of researchers has found a different way cancer becomes resistant to chemotherapy, suggesting a new target for drugs.
Cholesterol-cutting gene silencing treatment shows lasting effects
Twice-yearly injections of a cholesterol-cutting medication could offer patients lasting reduction in cholesterol, cutting risk of heart attacks.
Developing a vaccine revolution: Imperial experts take on global epidemics
Imperial’s work to develop smarter, more effective and flexible vaccines was showcased to a global audience from government, industry and charities.
Smart design could prevent drug resistance in new malaria treatments
Researchers have overcome malaria parasites’ resistance to potential new drugs by studying how it evolves.
ICB CDT student awarded BBSRC Flexible Talent Mobility Innovation Placement
ICB CDT student Mark Wilkinson has been awarded a BBSRC FTMA Innovation Placement and will spend 3 months attending the DDW unit at GSK, Madrid.
Researchers offered ‘quick and easy’ grants to get medical innovations started
A scheme is offering grants to help Imperial researchers test ideas for translating their research into new drugs, diagnostics or medical devices.
Video
Hit snooze to support World Cancer Day
This World Cancer Day, follow in the steps of Star Wars actor John Boyega and download the DreamLab App to conduct cancer research whilst your sleep.
Elephantiasis and river blindness could be eliminated faster with new molecule
A new potential drug molecule could reduce treatment times for two widespread diseases from weeks to days, ultimately helping to eliminate them.
2
Imperial and Bayer to accelerate drug discovery for heart conditions using AI
A new industrial partnership will use artificial intelligence (AI) to speed up drug discovery.
Breast cancer drug could create chink in the armour of pancreatic cancer
The well-known drug tamoxifen could exploit a weakness in the physical ‘scaffolds’ around tumours, according to research led by Imperial.
